Afirma enables individualized care and is supported by both ATA and NCCN guidelines
Afirma has helped over 150,000 patients conclusively rule out surgery or confidently tailor treatment4,6
Includes the most clinically relevant and emerging variants and fusions associated with thyroid carcinoma, such as:
Detects variants and fusions that may inform targeted therapy, such as:
References: 1. Patel KN, et al. JAMA Surg. 2018. 2. Haugen BR, et al. Thyroid 2016. 3. Bongiovanni M, et al. Acta Cytol. 2012. 4. Ali SZ, et al. Cancer Cytopathol. 2019. 5. Angell TE, et al. Front. Endocrinol. 2019. 6. Data on File. 7. Angell TE, et al. Thyroid 2019. 8. San Martin VT, et al. JCEM 2019. 9. Andrioli M, et al. Endocr. Pathol. 2020. 10. Wei S, et al. Cancer Cytopathol. 2019. 11. Harrell RM, et al. Endocr. Pract. 2018. 12. Endo M, et al. Thyroid 2019. 13. Hao Y, et al. BMC Syst. Biol. 2019. 14. TCGA Research Network. Cell 2014. 15. Wirth LJ, et al. ENDO 2020. 16. Goldner WS, et al. Thyroid 2019. 17. Yoo SK, et al. PLOS Genet. 2016.